Tuberculous meningitis

Journal of Epidemiology and Community Health

Volumn 68, Issue 3, 2014, Pages 195-196

  Van, Thinh Tran Thi ^a   Farrar, Jeremy ^a,b,c  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Singapore Infectious Diseases Initiative   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; CHILD; COST OF ILLNESS; DEVELOPING COUNTRY; EARLY DIAGNOSIS; EDITORIAL; HEALTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION CONTROL; INTERNATIONAL HLTH; METHODOLOGY; MIXED INFECTION; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICS; SURVIVAL; TUBERCULOSIS; TUBERCULOUS MENINGITIS;

INFECTION; INTERNATIONAL HLTH; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; CHILD; COINFECTION; COST OF ILLNESS; DEVELOPING COUNTRIES; EARLY DIAGNOSIS; HIV INFECTIONS; HUMANS; INFECTION CONTROL; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TUBERCULOSIS, MENINGEAL; WORLD HEALTH;

EID: 84894054982     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech-2013-202525     Document Type: Editorial

References (15)

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380:2095-128.
2. WHO. Global tuberculosis control: WHO report 2011. 2011.
3. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380:2197-223.
4. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004;351:1741-51.
5. Thwaites GE, Duc Bang N, Huy et al. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. J Infect Dis 2005;192:2134-41.
6. WHO. Treatment of tuberculosis guidelines. 4th edn. World Health Organization, 2010.
7. Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009;59:167-87.
8. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;13:27-35.
9. Heemskerk D, Day J, Chau TT, et al. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. Trials 2011;12:25.
10. Schoeman JF, Van Zyl LE, Laubscher JA, et al. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics 1997;99:226-31.
11. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471-81.
12. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011;52:1374-83.
13. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 1977;2:293-5.
14. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021-8.
15. Kaufmann SH. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis 2011;11:633-40.